- Home
- KNSA vs SLNO Comparison
KNSA vs SLNO Comparison
Compare KNSA & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNSA | SLNO |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.5B |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | KNSA | SLNO |
|---|---|---|
| Price | $43.54 | $49.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $51.33 | ★ $110.90 |
| AVG Volume (30 Days) | 399.9K | ★ 1.6M |
| Earning Date | 10-28-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $597,973,000.00 | $98,675,000.00 |
| Revenue This Year | $62.63 | N/A |
| Revenue Next Year | $29.93 | $155.86 |
| P/E Ratio | $92.52 | ★ N/A |
| Revenue Growth | ★ 55.68 | N/A |
| 52 Week Low | $17.82 | $41.50 |
| 52 Week High | $43.73 | $90.32 |
Technical Indicators
Market Signals| Indicator | KNSA | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 67.33 | 46.09 |
| Support Level | $40.77 | $48.60 |
| Resistance Level | $42.32 | $50.95 |
| Average True Range (ATR) | 1.45 | 2.64 |
| MACD | 0.12 | 0.23 |
| Stochastic Oscillator | 81.29 | 27.59 |
Price Performance
Historical ComparisonAbout KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.